Insider Selling: Bioventus Inc. (NYSE:BVS) CFO Sells $53,639.41 in Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 5,479 shares of the business’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $9.79, for a total transaction of $53,639.41. Following the sale, the chief financial officer now owns 131,963 shares of the company’s stock, valued at $1,291,917.77. This trade represents a 3.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Mark Leonard Singleton also recently made the following trade(s):

• On Tuesday, February 18th, Mark Leonard Singleton sold 6,498 shares of Bioventus stock. The stock was sold at an average price of $10.19, for a total transaction of $66,214.62.

Bioventus Stock Performance

Shares of NYSE BVS opened at $9.09 on Friday. The stock has a market cap of $744.87 million, a PE ratio of -14.90 and a beta of 0.86. Bioventus Inc. has a 1 year low of $3.90 and a 1 year high of $14.38. The firm has a fifty day moving average price of $10.09 and a 200-day moving average price of $10.98. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Institutional Investors Weigh In On Bioventus

A number of institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC lifted its position in shares of Bioventus by 11.3% in the fourth quarter. HighTower Advisors LLC now owns 13,617 shares of the company’s stock valued at $143,000 after acquiring an additional 1,380 shares in the last quarter. Principal Financial Group Inc. raised its stake in Bioventus by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 19,228 shares of the company’s stock valued at $202,000 after purchasing an additional 1,652 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company’s stock worth $36,000 after purchasing an additional 1,786 shares in the last quarter. EP Wealth Advisors LLC boosted its stake in Bioventus by 17.0% in the 4th quarter. EP Wealth Advisors LLC now owns 14,096 shares of the company’s stock worth $148,000 after purchasing an additional 2,047 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Bioventus by 26.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,194 shares of the company’s stock valued at $160,000 after buying an additional 3,153 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.